FG

Analyst Note: FG (F&G Annuities & Life, Inc.)

Date: 2026-06-13 Current Price: $27.49

1. Structural Readiness

State: Forming Aggressive/Pre-Breakout Entry: — (Not actionable on setup alone; requires confirmation) Breakout Level: — (Pending confirmation) Current Price: $27.49 Extension: — (Price is currently within the consolidation range; no extension above entry has occurred) ATR Context: Current ATR is 3.5% (Productive). This sits within the historical "sweet spot" (4–6% is the canonical high, but 3.5% indicates productive volatility without the extreme risk of >8% or the weakness of <2.5%).

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None named at this date. Analysis: This is not a secular-theme driven name in the current context. The investment case must be judged strictly on the quality of the structural setup (the forming coil) and the underlying business fundamentals as reported by management. There is no external macro thesis to weight the conviction; the focus is on the company's ability to execute its internal margin expansion and sales growth targets.

3. Business Overview

Company Profile: F&G Annuities & Life, Inc. operates as a subsidiary of Fidelity National Financial, Inc. The firm delivers a range of fixed annuity and life insurance products, specifically targeting the middle-income American demographic. Business Model: The company generates revenue through the sale of deferred annuities (Fixed Index Annuities and Fixed Rate Annuities), Indexed Universal Life (IUL) insurance, Immediate Annuities, Funding Agreements, and Pension Risk Transfer (PRT) solutions. Distribution Strategy: F&G leverages a network of Independent Marketing Organizations (IMOs) and has expanded its owned distribution strategy through majority and minority ownership stakes in IMOs. This provides a diversified earnings source with higher risk-adjusted returns compared to retained business. Key Metrics (as of Q1 2026 / FY 2025):

• Sales Growth: Gross sales reached $3.2 billion in Q1 2026 (up 10% YoY from $2.9 billion in Q1 2025). Full-year 2025 gross sales were $14.6 billion, up from $4.5 billion in 2020.
• AUM: Assets Under Management grew to nearly $75 billion at the end of Q1 2026, representing an 18% compound annual growth rate since 2019.
• Product Mix: In 2025, Fixed Index Annuities (FIAs) generated 46% of gross sales. Fixed rate annuities accounted for 26%, PRT for 15%, funding agreements for 12%, and IUL for 1%.
• Reinsurance: The company has reinsured over $15 billion of cumulative annuity new business to manage capital efficiency.
• Demographics: Management cites a demographic tailwind of over 4 million Americans turning 65 annually through 2027 (approx. 11,000 per day).

4. Archetype and Conviction

Archetype: Margin Inflector Rationale: The setup fits the "Margin Inflector" archetype based on management's explicit guidance regarding operating expense ratios and sales mix.

• Margin Expansion: Management expects the operating expense ratio to improve to approximately 45 basis points by year-end 2027.
• Sales Mix Shift: Management expects the mix of higher-margin products (likely FIAs and IULs) to grow to approximately 25% by year-end 2028.
• Valuation Context: The financial spine indicates a forward consensus EPS of $3.94 for FY1 and $5.15 for FY2. The company reported adjusted net earnings of $482 million for 2025 with an adjusted ROA of 87 basis points.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical only).
• *Evidence Quality:* High (Multiple primary earnings transcripts and SEC filings from May 2026 confirm growth and margin targets).
• *Structural Quality:* Moderate (Forming coil indicates accumulation, but breakout is pending).
• *Rerating Potential:* Moderate to High, contingent on the successful execution of the margin inflection and the realization of the $1.5B–$2B annual sales target.

5. Invalidations, Strengtheners, and Gaps

Gaps in Evidence:

• Breakout ATR: The ATR at the moment of breakout is not yet available as the breakout has not occurred.
• Detailed Capex/Guidance: While sales and expense targets are clear, specific capital expenditure plans or detailed lead-time expectations for the new business pipeline are not explicitly detailed in the provided evidence beyond general reinsurance deployment.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance for operating expense ratio to improve to 45 bps by year-end 2027; Q1 2026 gross sales up 10% YoY to $3.2 billion; AUM growing at 18% CAGR since 2019 reaching $75 billion. Sizing hint: Position size should reflect the "forming" status; smaller than a confirmed breakout trade, sized for the probability of a successful breakout rather than a guaranteed one. Expected path: Management expects the sales mix to shift toward higher-margin products, driving expense ratio improvement and earnings growth over the next 12-24 months. Expected horizon: 6 to 12 months for the setup to resolve (breakout or invalidation) and for margin targets to begin materializing.